Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time

International Journal of Cancer

Volumn 73, Issue 2, 1997, Pages 220-224

  Launoy, Guy ^a,c   Smith, Theresa C ^b   Diffy, Stephen W ^b   Bouvier, Véronique ^a  

^a INSERM   (France)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OCCULT BLOOD; PRIORITY JOURNAL;

AGED; COLORECTAL NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0030823435     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971009)73:2<220::AID-IJC10>3.0.CO;2-J     Document Type: Article

References (22)

1. ALBERT, A., GERTMAN, P.M. and Louis, T.A., Screening for the early detection of cancer. I. The temporal natural history of a progressive disease state. Math. Biosci., 40, 1-59 (1978).
2. ALLISON, J.E., TEKAWA, I.S., RANSOM, L.J. and ADRAIN, A.L., A comparison of fecal occult-blood tests for colorectal cancer screening. N. Engl. J. Med., 334, 155-159 (1996).
3. BUFFIL, J.A., Colorectal cancer, evidence for distinct genetic categories based on proximal or distal tumor location. Ann. intern. Med., 114, 431-432 (1991).
4. DAY, N.E. and WALTER, S.D., Simplified models of screening for chronic disease, estimation procedures from mass screening programmes. Biometrics, 43, 1-56 (1984).
5. DUFFY, S.W., CHEN, H.H., TABAR, L. and DAY, N.E., Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statist. Med., 14, 1531-1534 (1995).
6. GELFAND, A.E. and SMITH, A.F.M., Sampling based approaches to calculating marginal densities. J. Amer. Statist. Ass., 85, 398-409 (1990).
7. HARDCASTLE, J.D., CHAMBERLAIN, J.O., ROBINSON, M.H., Moss, S.M., AMAR, S.S., BALFOUR, T.W., JAMES, P.D. and MANGNAM, C.M., Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 348, 1472-1477 (1996).
8. INOUE, M., TAJIMA, K., HIROSE, K., HAMAJINA, M., TAKEZATI, T., HIRAT, T., KATO, T. and OHNO, Y., Subsite-specific risk factors for colorectal cancer, a hospital-based case-control study in Japan. Cancer Causes Control, 6, 14-22 (1995).
9. KEWENTER, J., BREVINGE, H., ENGARAS, B., HAGLIND, E. and AHREN, C., Results of screening, rescreening and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Scand. J. Gastroenterol., 29, 468-173 (1994).
10. KRONBORG, O., FENCER, C., OLSEN, J., JORGHNSEN, O.D. and SONDERGAARD, O., Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet, 348, 1467-1471 (1996).
11. LAUNOY, G., HERBERT, C., VALLÉE, J.P., DESOUBEAUX, N., REAUD, J.M., OLLIVIER, V., BOUVIER, V., FLACHS, A., ARSÈNE. D., VALLA, A. and GIGNOUX, M., Le dépistage de masse du cancer colorectal en France. Experience auprès de 165.000 personnes dans le Calvados. Gastroenterol. clin. Biol., 20, 228-236 (1996).
12. MANDEL, J.S., BOND, J.H., BRADLEY, M., SNOVER, D.C., CHURCH, T.R., WILLIAMS, S., WATT, G., SCHUMAN, L.M., EDERER, F. and GILBERTSEN, V., Sensitivity, specificity and positive predictivity of the haemoccult test in screening for colorectal cancers. Gastroenterology, 97, 597-600 (1989).
13. MANDEL, J.S., BOND, J.H., CHURCH, T.R., SNOVER, D.C., BRADLEY, M., CHURCH, T.R., SCHUMAN, L.M. and EDERER, F., Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med., 328, 1365-1371 (1993).
14. NAKAMA, H., KAMIJO, N., FATTAH, A.S.M.A. and ZHANG, B., Validity of immunological faecal occult blood screening for colorectal cancer, a follow-up study. J. med. Screening, 3, 63-65 (1996).
15. PACI, E. and DUFFY, S.W., Modelling the analysis of breast cancer screening programmes, sensitivity, lead time and predictive value in the Florence district programme. Int. J. Epidemiol., 20, 852-858 (1991).
16. POCARD, M., SALMON, R.J. and POUPON, M.F, Deux types d' adénocarcinome colique, Arguments et implications. Gastromenterol. clin. Biol., 19, 3-6 (1995).
17. PONZ DE LEON, M., SACCHETTI, C., SASSATELLI, R., ZANGHIERI, G., RON-CUCCI, L. and SCALMATI, A., Evidence for the existence of different types of large bowel tumor, suggestions from the clinical data of a population-based registry. J. surg. Oncol., 44, 35-43 (1990).
18. ROBINSON, M.H.E., MARKS, C.G., FARRANDS, P.A., BOSTOCK, K. and HARDCASTLE, J.D., Screening for colorectal cancer with an immunological faecal occult blood test, 2-year follow-up. Brit. J. Surg., 83, 500-501 (1996).
19. ROBINSON, M.H.E., Moss, S.M., HARDCASTLE, J.D., WHYNES, D.K., CHAMBERLAIN, J.O. and MANGHAM, C.M., Effect of retesting with dietary restriction in haemoccult screening for colorectal cancer. J. med. Screening, 2, 41-44 (1995).
20. SHAPIRO, S.A.M., GOLDBERG, J.D. and HUDCHISON, G.B., Lead time in breast cancer detection and implication for periodicity of screening. Amer, J. Epidemiol., 100, 357-366 (1974).
21. THOMAS, W.M., PYE, G., HARDCASTLE, J.D. and WALKER, A.R., Screening for colorectal carcinoma, an analysis of the sensitivity of haemoccult. Brit. J.Surg., 79, 833-835 (1992).
22. WALTER, S.D. and DAY, N.E., Estimation of the duration of a preclinical disease state using screening data. Amer. J. Epidemiol., 118, 865-885 (1983).